SGIOY News and Press, Shionogi & Co. Ltd. ADR

2026-02-25 15:50:28 ET More on GSK, Pfizer Pfizer: A Risky 6.3% Yield For Income-Oriented Investors Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround ...

2026-02-02 07:31:09 ET More on Shionogi & Co. Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake Seeking Alpha’s Quant Rating on Shionogi & Co. Historical earnings data for Shionogi & Co. Dividend scorecard for S...

2026-01-20 13:30:02 ET More on Pfizer, GSK, etc. Pfizer: Rebound Has Just Started Pfizer: The Most Intriguing Value Play Of 2026 GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript RFK Jr. has reportedly removed four members of ...

Celestica Inc. (CLS) is expected to report $1.33 for Q3 2025 Universal Health Services Inc. (UHS) is expected to report $4.66 for Q3 2025 Dorman Products Inc. (DORM) is expected to report $2.31 for Q3 2025 Avis Budget Group Inc. (CAR) is expected to report $8.11 for Q3 2025 Two Ha...

2025-10-16 12:18:38 ET More on Roche Holding Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon? Roche Holding AG (RHHBY) Discusses On Pharma Day 2025 (Transcript) Roche Holding AG (RHHBY) Special Call - Slideshow Roche, Eli Lilly Alzheimer's blood diagn...

2025-10-15 07:49:59 ET More on Pfizer, GSK, etc. GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview) GSK's Hidden Growth Engines Beyond HIV And Oncology Pfizer ...

2025-09-26 04:59:57 ET More on drugmakers AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcri...

2025-07-29 08:35:31 ET Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 03:30 AM ET Company Participants John A. Keller - Senior Exec. Officer, SVP of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director Masako Kudou ...

Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q1 2026

2025-07-28 04:34:00 ET More on Shionogi & Co. ViiV expands license to produce generic Apretude in low-income countries Key deals this week: Sunoco, TaskUS, BP, DoorDash, Gold Fields and more Seeking Alpha’s Quant Rating on Shionogi & Co. Hi...